Bone Abstracts

Aim: To assess the relationships of serum osteoprotegerin (OPG), receptor-activator of nuclear factor-κB ligand (RANKL) and tumor necrosis factor-alpha (TNF-α) superfamily with bone composition in end-stage COPD.Methods: Body and bone composition, serum OPG, RANKL, TNF-α and its receptors (sTNFR I, sTNFR II), TNF-related apoptosis-inducing ligand (sTRAIL) levels were measured in 48 men end-stage COPD accepted for lung transplantation, and ...

Objective: The study evaluated the efficacy of the therapeutic compliance in brittle bone disease applied to frail elderly people affected by osteoporosis and in treatment with Denosumab.Methods: We studied people ≥75; 43 women (mean age 83±3) and 14 men (mean age 85±3), all suffering from femoral osteoporosis T-score <−4. In 34 women and 6 men, we discovered 1–2 vertebral fractures. They have been treated with Den...

Objective: The BoneXpert method for automated bone age determination from hand X-rays also determines the cortical thickness T and the bone width W in the three middle metacarpals. From these, the method derives the cortical area A=π W T (1 – T/W), the metacarpal index MCI =A/(WW) and the Bone Health Index. Recently, the method has been extended down to new-borns, and the aim of this study is to report reference curves for these bone measures.M...

Ankylosing spondylitis is a chronic inflammatory rheumatic disease, characterized by axial pain and osteoproliferation, leading to painful rigidity of the spine and disability. In contrast with this bone formation, bone loss is an early event in this disease, and an increased vertebral fracture risk (but not non-vertebral fracture risk) has been reported in these patients.Prospective studies have shown that potent anti-inflammatory drugs, such as anti-TN...

The aim of this study was to evaluate the trabecular bone score (TBS), bone mineral density (BMD) and body composition in women of various ages.Materials and methods: 494 women aged 41–89 years (mean age, 63.6±0.4 years; mean height, 1.61±0.003 m; and mean weight, 74.0±0.6 kg) were examined. The patients were divided into the following age-dependent groups: 40–49 years (n=35), 50–59 years (n=130), 60–6...

Introduction: Administration of antibodies that neutralize sclerostin has been demonstrated to increase bone mass. We report the key findings of a Phase 2 study of the human sclerostin antibody, blosozumab (bmab).Methods: Study GSDB was a randomized, parallel-design, double-blind placebo-controlled study, designed to assess the dose–response relationship of bmab in postmenopausal women with low bone mineral density (BMD; lumbar spine (LS) T...

Objective: The purpose of this study was to investigate the association between single nucleotide polymorphisms (SNPs) in leptin (LEP), its receptor (LEPR) and β adrenergic receptor (ADRB) genes and bone mineral density (BMD) in postmenopausal Korean women.Methods: The LEP c.280G>A, LEPR c.326A>G, c.668A>G, c.1968G>C, c.2096C>T, ADRB2 c.46A>G, c.79C>G, c.718T>C, c....

Introduction: Recently reported high incidences of hip fractures emphasize the need of more effective methods for osteoporosis diagnosis, currently performed essentially by dual-energy X-ray absorptiometry (DXA) examinations of the proximal femur. However, high costs and radiation-related issues do not allow DXA employment for population mass screenings. Aim of this study is to carry out a preliminary clinical validation of a new ultrasound (US)-based method to perform femoral...

Introduction: Currently, the only available method to reliably predict osteoporotic fractures is represented by bone mineral density (BMD) measurements on proximal femur or spine, which require the use of X-rays. Aim of this study is to illustrate working principles and feasibility of a new ultrasound (US) method for bone densitometry and osteoporosis diagnosis applicable on both proximal femur and spine.Methods: A new fully automatic algorithm was devel...

Introduction: Evidence in literature shows how is useful to use antiresorptive drugs such as bisphosphonates, in severe osteoporosi severe after PTH (1–34 or 1–84) treatment.Methods: This study was divided into two parts: the first one analyzed BMD changes by DXA at the lumbar and femoral and serum osteocalcin and β-CTX, monitoring their performance after 6, 12 and 18 months in 71 women with severe postmenopausal osteoporosis, treated for ...